Conrad Biotech Pte Ltd is a Singaporean biopharmaceutical company that offers technologies development including stem cells, immune cells and small molecule antibodies for regenerative medicine and cancer treatments. Our technologies cover a few pre-clinical validation and early-phase assessment of indications such as ischemic stroke, acute myocardial infraction, Parkinson's disease, multiple sclerosis, ostero arthritis, and both liquid and solid cancers. Conrad’s research and core technologies continually ensure public safety and feasibility in patient conditioning. Moreover, Conrad is committed to establish a better technology platform for developing the next generation drugs and treatments for cerebrovascular, cardiovascular diseases, and to seek possible transformation turning fatal cancers to chronic illness for the wellbeing of cancers patients.